Welcome to the 2026 Pipeline Report. Our annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). All these updates are downloadable PDFs, and we’ll…
Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. These storyboards follow three individuals journeys through diagnosis, treatment and care, and the barriers they face.
On June 4, 2025, the Cure Hepatitis C Act of 2025/2026 (S.1941/H.R.9682) was introduced with bipartisan cosponsorship in both chambers. While this is the most comprehensive hepatitis C virus (HCV) specific bill ever introduced in Congress, it requires significant changes…
Treatment Action Group (TAG) welcomes the introduction of the House companion to the Cure Hepatitis C Act (S.1941) and applauds Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Hank Johnson (D-GA), and Don Bacon (R-NE) for advancing bipartisan legislation to eliminate hepatitis C in the United States. We are particularly encouraged that the House bill removes the immigration-based eligibility restrictions contained in Section 10 of the Senate version — an important improvement that brings the legislation closer to the public health principles necessary to achieve hepatitis C virus (HCV) elimination in the United States in our lifetimes.
The United States is currently at an inflection point in Hepatitis C virus (HCV) response. We have the tools for rapid and accurate diagnosis, safe and effective cure, and prevention. These tools are only as useful as access to them can be, which is why the Cure Hepatitis C Act (S.1941) holds so much promise.
TAG and the Long-Acting Therapies Community Advisory Board (LAT CAB) welcomed a decision by the Indian Patent Office rejecting a patent application related to the hepatitis C treatment combination glecaprevir/pibrentasvir (G/P). Advocates say the decision could help reduce barriers to generic competition, lower treatment costs, and expand access to hepatitis C treatment in low- and middle-income countries disproportionately affected by the epidemic.
Treatment Action Group’s (TAG) HIV team works across the country to achieve a shared mission: end the HIV epidemic through science, policy, and advocacy. As a remote team, the reach is national but the urgency is personal. At a time when progress is possible and precarious, the team ensures that research translates into action for impacted communities.
TAG's leadership and staff broke down the latest in HIV, TB, and hepatitis C research and advocacy. See where the work stands and where it's headed.
CDC pauses rabies, mpox, and other infectious disease testing amid budget cuts and staffing losses, raising urgent public health concerns.
TAG recommends that the AIDS Research Advisory Council (ARAC) endorse NIAID's continued support of a balanced and comprehensive portfolio of basic, clinical, and implementation science — including a funding opportunity to renew its four current networks: the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT), the HIV Prevention Trials Network (HPTN), and the HIV Vaccine Trials Network (HVTN) or the updated IBPTN.
Your donation will bring progress, healing, and hope — turning the promise of innovative research into a brighter, healthier future for all.
